Detalhe da pesquisa
1.
A genome-scale screen for synthetic drivers of T cell proliferation.
Nature;
603(7902): 728-735, 2022 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35296855
2.
The bone marrow microenvironment at single-cell resolution.
Nature;
569(7755): 222-228, 2019 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30971824
3.
Author Correction: The bone marrow microenvironment at single-cell resolution.
Nature;
572(7767): E6, 2019 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31296938
4.
Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas.
Br J Haematol;
204(5): 1762-1770, 2024 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38500476
5.
Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers.
Blood;
137(3): 374-386, 2021 01 21.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32663292
6.
Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma.
Am J Hematol;
98(3): 464-471, 2023 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36629030
7.
Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study.
Haematologica;
106(7): 1932-1942, 2021 07 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33538152
8.
Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure.
Cancer;
126(2): 293-303, 2020 01 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31568564
9.
Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy.
Br J Haematol;
191(1): 44-51, 2020 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32430944
10.
Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy.
Oncologist;
25(10): 878-885, 2020 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32720734
11.
Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma.
Oncologist;
25(6): e993-e997, 2020 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32275786
12.
Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma.
Blood;
132(3): 293-306, 2018 07 19.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29695516
13.
Advances in Therapy for Relapsed or Refractory Hodgkin Lymphoma.
Curr Oncol Rep;
22(1): 6, 2020 01 24.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31981025
14.
Role of anthracycline and comprehensive geriatric assessment for elderly patients with diffuse large B-cell lymphoma.
Blood;
130(20): 2180-2185, 2017 11 16.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28814386
15.
Potentially inappropriate medication use in elderly non-Hodgkin lymphoma patients is associated with reduced survival and increased toxicities.
Br J Haematol;
180(2): 267-270, 2018 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29143301
16.
Expanding landscape for relapsed Hodgkin lymphoma.
Blood;
138(6): 421-422, 2021 08 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34383039
17.
Safety and efficacy of polatuzumab vedotin + obinutuzumab for relapsed/refractory non-Hodgkin lymphomas: A phase IB/II study.
Am J Hematol;
97(1): E24-E27, 2022 01 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34731510
18.
Checkpoint Inhibition in Hodgkin Lymphoma: Saving the Best for Last?
Oncology (Williston Park);
30(10): 914-20, 2016 10 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27753058
19.
Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era.
Br J Haematol;
171(4): 530-8, 2015 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26343802
20.
CART19 in Hodgkin lymphoma: are we driving the right model?
Blood;
132(10): 982-983, 2018 09 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30190350